off-the-wire

Sanofi Q1 profit buoyed by better-than-expected Dupixent sales

Kitco Media
By Reuters
Published:
Updated:
Reuters
April 27 (Reuters) - French drugmaker Sanofi on Thursday posted better-than-expected earnings for the first quarter as continued gains from anti-inflammatory drug Dupixent more than offset declining sales from an established multiple sclerosis drug.


It reported an 8.7% rise in quarterly business operating income, or adjusted earnings before interest and tax, to 3.33 billion euros ($3.7 billion), ahead of an average analyst estimate of 3.14 billion posted on the company's website. Revenue from eczema and asthma drug Dupixent, jointly developed with Regeneron , surged more than 43% to 2.32 billion euros, above a consensus of 2.27 billion euros.


The Paris-based drugmaker said on Thursday it still expected 2023 adjusted earnings per share to grow by a "low single digit" percentage, not taking into account an expected negative currency impact of between 5.5% and 6.5%. It had previously flagged a negative currency impact of between 3.5% and 4.5%.


($1 = 0.9049 euros) (Reporting by Ludwig Burger; Editing by Jacqueline Wong)

Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.